Clinical trial
Bicalutamide in Treating Patients With Metastatic Breast Cancer
NCT00468715 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00468715 |
|---|---|
| Title | Bicalutamide in Treating Patients With Metastatic Breast Cancer |
| Official title | Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining method |
| Enrollment | 28 |
| Start date | Mar 23, 2007 |
| Primary completion | Jun 24, 2021 |
| Completion | Jun 24, 2021 |
| First posted | May 3, 2007 |
| Last update posted | Aug 3, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: